Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. (Q48395487)

11 February 2018

review article

1 reference

title

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. (English)

1 reference

11 February 2018

1 reference

Polinsky RJ

1

1 reference

11 February 2018

publication date

1 July 1998

1 reference

11 February 2018

published in

Clinical Therapeutics

1 reference

11 February 2018

volume

20

1 reference

11 February 2018

issue

4

1 reference

11 February 2018

page(s)

634-647

1 reference

11 February 2018

Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

7 January 2021

Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

7 January 2021

The US economic and social costs of Alzheimer's disease revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

7 January 2021

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

7 January 2021

The cholinergic hypothesis--ten years on.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

7 January 2021

Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

1 reference

7 January 2021

Pharmacologic and Clinicopharmacologic Properties of SDZ ENA 713, a Centrally Selective Acetylcholinesterase Inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

7 January 2021

Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

7 January 2021

The Molecular Forms of Cholinesterase and Acetylcholinesterase in Vertebrates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

7 January 2021

Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: selective loss of the intermediate (10S) form

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

7 January 2021

Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

7 January 2021

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980127-6

7 January 2021

10.1016/S0149-2918(98)80127-6

Identifiers

DOI

1 reference

11 February 2018

PubMed ID

9737824

1 reference

11 February 2018